These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Evidence that long-lasting potentiation in limbic circuits mediating defensive behaviour in the right hemisphere underlies pharmacological stressor (FG-7142) induced lasting increases in anxiety-like behaviour: role of benzodiazepine receptors. Adamec RE J Psychopharmacol; 2000; 14(4):307-22. PubMed ID: 11198048 [TBL] [Abstract][Full Text] [Related]
50. Ro 15-4513, like anxiogenic beta-carbolines, increases dopamine metabolism in the prefrontal cortex of the rat. Giorgi O; Corda MG; Biggio G Eur J Pharmacol; 1988 Oct; 156(1):71-5. PubMed ID: 3208840 [TBL] [Abstract][Full Text] [Related]
51. The anxioselective agent 7-(2-chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) is more efficacious than diazepam at enhancing GABA-gated currents at alpha1 subunit-containing GABAA receptors. Popik P; Kostakis E; Krawczyk M; Nowak G; Szewczyk B; Krieter P; Chen Z; Russek SJ; Gibbs TT; Farb DH; Skolnick P; Lippa AS; Basile AS J Pharmacol Exp Ther; 2006 Dec; 319(3):1244-52. PubMed ID: 16971504 [TBL] [Abstract][Full Text] [Related]
52. Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humans. Atack JR; Wong DF; Fryer TD; Ryan C; Sanabria S; Zhou Y; Dannals RF; Eng WS; Gibson RE; Burns HD; Vega JM; Vessy L; Scott-Stevens P; Beech JS; Baron JC; Sohal B; Schrag ML; Aigbirhio FI; McKernan RM; Hargreaves RJ J Pharmacol Exp Ther; 2010 Jan; 332(1):17-25. PubMed ID: 19779131 [TBL] [Abstract][Full Text] [Related]
54. Bidirectional effects of benzodiazepine binding site ligands in the passive avoidance task: differential antagonism by flumazenil and beta-CCt. Savić MM; Obradović DI; Ugresić ND; Cook JM; Yin W; Bokonjić DR Behav Brain Res; 2005 Mar; 158(2):293-300. PubMed ID: 15698896 [TBL] [Abstract][Full Text] [Related]
55. Modulation of mesoprefrontal dopamine neurons by central benzodiazepine receptors. I. Pharmacological characterization. Tam SY; Roth RH J Pharmacol Exp Ther; 1990 Mar; 252(3):989-96. PubMed ID: 2157001 [TBL] [Abstract][Full Text] [Related]
56. Pharmacological studies on stress-induced increase in frontal cortical dopamine metabolism in the rat. Claustre Y; Rivy JP; Dennis T; Scatton B J Pharmacol Exp Ther; 1986 Aug; 238(2):693-700. PubMed ID: 2874216 [TBL] [Abstract][Full Text] [Related]
57. Selective increase in dopamine utilization in the shell subdivision of the nucleus accumbens by the benzodiazepine inverse agonist FG 7142. Horger BA; Elsworth JD; Roth RH J Neurochem; 1995 Aug; 65(2):770-4. PubMed ID: 7616234 [TBL] [Abstract][Full Text] [Related]
58. Pharmacology of the beta-carboline FG-7,142, a partial inverse agonist at the benzodiazepine allosteric site of the GABA A receptor: neurochemical, neurophysiological, and behavioral effects. Evans AK; Lowry CA CNS Drug Rev; 2007; 13(4):475-501. PubMed ID: 18078430 [TBL] [Abstract][Full Text] [Related]
59. 3-Ethoxy-beta-carboline: a high affinity benzodiazepine receptor ligand with partial inverse agonist properties. Trullas R; Ginter H; Jackson B; Skolnick P; Allen MS; Hagen TJ; Cook JM Life Sci; 1988; 43(15):1189-97. PubMed ID: 2845211 [TBL] [Abstract][Full Text] [Related]
60. The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Atack JR Expert Opin Investig Drugs; 2005 May; 14(5):601-18. PubMed ID: 15926867 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]